热疗联合化疗治疗卵巢癌的Meta分析

摘要

Objective To assess the effectiveness and safety of hyperthermia combined with chemotherapy(HCT)compared with chemotherapy (CT)for ovarian cancer. Methods Related literatures were searched by two independent investigators from the following electronic databases:PubMed,Cochrane Library,EMbase,VIP,WanFang Data,CNKI and CBM.Then the meta⁃analysis was performed by using RevMan 5.3 software. Results A total of 10 RCTs involving 546 patients were included. The results of Meta⁃analysis showed that the HCT group was superior to the CT group in the effective rate,tumor control rate,effective rate of CA125,ascites control rate and PD,with significant differences(P<0.05). There was no significant difference in the improvement rate of life quality and the incidences of myelosuppression,severe myelosuppression,severe nausea and vomiting,severe constipation and diarrhea,liver and renal damage(P>0.05). Conclusion Compared with CT,HCT can significantly increase short⁃term curative effect,ameliorate the quality of life,and it does not increase the incidence of adverse reactions. HCT is worthy of clinical applica⁃tion.%目的：系统评价热疗联合化疗（HCT）与单纯化疗（CT）治疗卵巢癌的有效性和安全性。方法由2名研究员根据文献纳入标准独立检索PubMed、The Cochrane Library、EMbase、VIP、WanFang Data、CNKI和CBM等数据库的文献，应用RevMan5.3软件进行Meta分析。结果共纳入10个RCT，546例患者。Meta分析结果显示：HCT组的有效率、肿瘤控制率、CA125有效率、腹水控制率优于CT组，肿瘤进展率低于CT组，差异均有统计学意义（P<0.05）；2组在生活质量改善率、骨髓抑制、重度骨髓抑制、重度恶心呕吐、重度便秘腹泻、肝肾功损害发生率方面差异均无统计学意义（P>0.05）。结论 HCT较CT可明显提高卵巢癌患者的近期疗效，改善生活质量，且不增加不良反应，值得临床推广应用。